Price
No data yet.
Social Signal Score
Analyst Ratings
25 analystsRevenue
$2.27M+479.59%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Paul Bolno
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 317
- Beta
- -1.30
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 0.58
Financials
Revenue
$2.27M+479.6%Net Income
$-69.36MEBITDA
$-71.22MFree Cash Flow
$-49.22MEPS (diluted)
$-0.34Shares Outstanding (diluted)
202.10M+762.0%Operating Expenses
$76.07MCash & Debt
$490.60MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $42.73M | $-204.38M | $-1.21 |
| 2024 | $108.30M | $-97.01M | $-0.70 |
| 2023 | $113.31M | $-57.51M | $-0.54 |
| 2022 | $3.65M | $-161.82M | $-2.05 |
| 2021 | $40.96M | $-122.25M | $-2.36 |
| 2020 | $20.08M | $-149.91M | $-3.82 |
| 2019 | $15.98M | $-193.64M | $-5.30 |
| 2018 | $14.41M | $-146.65M | $-5.06 |
| 2017 | $3.70M | $-102.03M | $-3.85 |
| 2016 | $1.49M | $-55.40M | $-2.43 |
| 2015 | $152.0K | $-19.20M | $-0.89 |
| 2014 | $0.00 | $-5.23M | $-0.25 |
| 2013 | $0.00 | $-3.32M | $-0.93 |
Valuation
WVEhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120+50.00%Social Signal Score
Mentions (6)
- Newsglobenewswire.com·5d ago·Positive
Wave Life Sciences Announces FDA Feedback Supports Registrational Pathway for WVE-006 (RNA Editing) in AATD Following meeting with FDA, Wave plans for a single, two-year registrational trial, with a one-year interim analysis for potential accelerated approval based on AATD biomarkers
View source ↗ - Newsglobenewswire.com·13d ago·Negative
Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for Obesity WVE-007 induces fat loss without muscle loss, with clinical data supporting 1-2x per year dosing; preclinical data demonstrate Wave's INHBE GalNAc-siRNA in combination with GLP-1 doubled weight loss compared with GLP-1 alone
View source ↗ - Newsglobenewswire.com·14d ago·Neutral
Wave Life Sciences Announces Appointment of Dr. Monika Vnuk as Chief Business Officer Dr. Vnuk brings substantial business and corporate development leadership experience from Sanofi, Blackstone, and Pfizer CAMBRIDGE, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd.
View source ↗ - News247wallst.com·54d ago·Positive
Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover Wave Life Sciences (NASDAQ:WVE) trades at $5.24, a step above its 52-week low of $5.01 and far beneath the 52-week high of $21.73.
View source ↗ - Newsseekingalpha.com·55d ago·Positive
Wave Life Sciences Ltd. (WVE) Presents at Bank of America SMID Cap Virtual Conference Transcript Wave Life Sciences Ltd. (WVE) Presents at Bank of America SMID Cap Virtual Conference Transcript
View source ↗ - Newsglobenewswire.com·57d ago·Negative
Wave Life Sciences Announces Completion of Redomiciliation to Delaware CAMBRIDGE, Mass., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (NASDAQ: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health (“Wave” or “Wave Life Sciences”), today announced the completion of the redomiciliation process to change the parent company of the Wave group of companies from a Singapore company to a Delaware corporation by way
View source ↗
Earnings
Mon, Nov 9(in 5 weeks)
Consensus estimate $-0.33 per share
Typical surprise -6.9% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 30$-0.34 vs $-0.30miss
- Tue, Apr 28$-0.13 vs $-0.34beat
- Thu, Feb 26$-0.30 vs $-0.28miss
- Mon, Nov 10$-0.32 vs $-0.30miss
- Wed, Jul 30$-0.31 vs $-0.29miss
- Thu, May 8$-0.29 vs $-0.27miss
Estimates and results for WVE via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by WVE officers and directors.
- Bought
- $82.6m
- Sold
- $10.7m
5 trades
32 trades
- Rawcliffe Adriansold
- Wagner Heidi Lsold
- Takanashi Kensold
- Tan Aik Nasold
- Ra Capital Management, L.p.bought
- Ra Capital Management, L.p.bought
- Ra Capital Management, L.p.bought
- Ra Capital Management, L.p.bought
63 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in WVE.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.